human dnam Search Results


pe cd226  (Miltenyi Biotec)
93
Miltenyi Biotec pe cd226
Pe Cd226, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe cd226/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
pe cd226 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human dnam  (R&D Systems)
94
R&D Systems human dnam
Human Dnam, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dnam/product/R&D Systems
Average 94 stars, based on 1 article reviews
human dnam - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti dnam 1 pe rea1040  (Miltenyi Biotec)
94
Miltenyi Biotec anti dnam 1 pe rea1040

Anti Dnam 1 Pe Rea1040, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti dnam 1 pe rea1040/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti dnam 1 pe rea1040 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti dnam 1 apc  (Miltenyi Biotec)
93
Miltenyi Biotec anti dnam 1 apc

Anti Dnam 1 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti dnam 1 apc/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti dnam 1 apc - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
cd226 vioblue  (Miltenyi Biotec)
94
Miltenyi Biotec cd226 vioblue
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Cd226 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd226 vioblue/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd226 vioblue - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
146nd cd226 rea1040  (Miltenyi Biotec)
94
Miltenyi Biotec 146nd cd226 rea1040
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
146nd Cd226 Rea1040, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/146nd cd226 rea1040/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
146nd cd226 rea1040 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
biotinylated hu cd226  (Sino Biological)
94
Sino Biological biotinylated hu cd226
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Biotinylated Hu Cd226, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated hu cd226/product/Sino Biological
Average 94 stars, based on 1 article reviews
biotinylated hu cd226 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
dnam 1 pe vio770  (Miltenyi Biotec)
93
Miltenyi Biotec dnam 1 pe vio770
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Dnam 1 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dnam 1 pe vio770/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
dnam 1 pe vio770 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
cd112  (R&D Systems)
90
R&D Systems cd112
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Cd112, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd112/product/R&D Systems
Average 90 stars, based on 1 article reviews
cd112 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dnam 1  (Miltenyi Biotec)
94
Miltenyi Biotec dnam 1
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Dnam 1, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dnam 1/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
dnam 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human dnam  (R&D Systems)
93
R&D Systems recombinant human dnam
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Recombinant Human Dnam, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human dnam/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant human dnam - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant human dnam 1 fc  (R&D Systems)
94
R&D Systems recombinant human dnam 1 fc
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Recombinant Human Dnam 1 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human dnam 1 fc/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human dnam 1 fc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Journal: iScience

Article Title: Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34 + progenitor cell-derived NK cells

doi: 10.1016/j.isci.2023.107078

Figure Lengend Snippet:

Article Snippet: To characterize receptor expression profile on NK cells, the following antibodies were used: anti-CD45 KO (J.33), anti-CD56 APCA750 (N901), anti-NKG2D PE (ON72), anti-NKp44 PE (Z231), anti-NKG2A PE (Z199), anti- KIR2DL1 KIR2DS1 PE (EB6.B) (all from Beckman Coulter), anti-DNAM-1 PE (REA1040) (Miltenyi Biotec B.V.), anti-NKp30 BV605 (p30-15), anti-NKp46 BV786 (9E2), anti-FASL BV605 (NOK-1), anti-TRAIL BV786 (RIK-2) (all from BD Biosciences) and 7-aminoactinomycin D (7-AAD; Sigma).

Techniques: Virus, Recombinant, Multiplexing, Activity Assay, Software

Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and CD226 expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).

Journal: Cancers

Article Title: Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

doi: 10.3390/cancers15030904

Figure Lengend Snippet: Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and CD226 expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).

Article Snippet: Incubation with the following antibodies in a total volume of 100 μL was conducted for 20 min at RT: CD3-VioGreen (REA613, 1:200), CD56-APC-Vio770 (REA196, 1:200), CD226-VioBlue (REA1040, 1:50); CD335 (NKp46)-Vio Bright B515 (REA808, 1:50), CD337 (NKp30)-PE (REA823, 1:75), CD336 (NKp44)-APC (REA1163, 1:75), and CD314 (NKG2D)-PE-Vio 770 (REA1228, 1:75), all from Miltenyi Biotec.

Techniques: Cell Culture, Expressing, Flow Cytometry, Fluorescence, Control